Literature DB >> 10830216

A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants.

S M Kang1, D Braat, D B Schneider, R W O'Rourke, Z Lin, N L Ascher, D A Dichek, S Baekkeskov, P G Stock.   

Abstract

BACKGROUND: Fas ligand (FasL) mediates apoptosis of susceptible Fas-expressing lymphocytes, and may contribute to the maintenance of peripheral tolerance. In transplantation models, however, artificial expression of FasL on cellular as well as islet transplants results in accelerated rejection by neutrophils. The mechanism of the neutrophilic response to FasL expression is unknown. FasL, like other members of the tumor necrosis factor family, is cleaved to a soluble form by metalloproteases. We tested the hypothesis that soluble FasL (sFasL) was responsible for neutrophil migration by creating a non-cleavable mutant of FasL.
METHODS: Three mutants of FasL with serial deletions in the putative proteolytic cleavage site of human FasL were made using inverse polymerase chain reaction. The relative fractions of sFasL and membrane-bound FasL were assessed by Western blot and immunoprecipitation, as well as by cytotoxicity assay using Fas-expressing target cells. The fully non-cleavable mutant was transduced into murine islets as well as myoblasts and tumor cell lines, and tested in a murine transplantation model.
RESULTS: Serial deletions in the putative metalloprotease site of FasL resulted in a fully non-cleavable mutant of FasL (ncFasL). Expression of ncFasL in tumor lines induced higher levels of apoptosis in Fas bearing targets than wild-type FasL. Transplantation of ncFasL-expressing islets under the kidney capsule of allogenic mice resulted in accelerated rejection identical to that seen with wild-type Fas ligand-expressing islets. Myoblasts and tumor cell lines expressing ncFasL also induced neutrophil infiltration.
CONCLUSIONS: Membrane-bound Fas ligand is fully capable of inducing a neutrophilic response to transplants, suggesting an activation by Fas ligand of neutrophil chemotactic factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10830216     DOI: 10.1097/00007890-200005150-00014

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.

Authors:  Esma S Yolcu; Hong Zhao; Laura Bandura-Morgan; Chantale Lacelle; Kyle B Woodward; Nadir Askenasy; Haval Shirwan
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

2.  Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy.

Authors:  Chae Young Kim; Soon Hye Park; Moonsup Jeong; O Seo Kwon; Hyounmie Doh; Su Hyung Kang; Paul D Robbins; Byong Moon Kim; Dai Wu Seol; Byung Gee Kim
Journal:  Exp Mol Med       Date:  2011-10-31       Impact factor: 8.718

3.  Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.

Authors:  Peter J Dupont; Anthony N Warrens
Journal:  Immunology       Date:  2007-01       Impact factor: 7.397

Review 4.  The Fas/Fas ligand system and cancer: immune privilege and apoptosis.

Authors:  Vikki M Abrahams; Marijke Kamsteeg; Gil Mor
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

5.  Posttransplantation systemic immunomodulation with SA-FasL-engineered donor splenocytes has robust efficacy in preventing cardiac allograft rejection in mice.

Authors:  H Zhao; K B Woodward; H Shirwan; O Grimany-Nuno; E S Yolcu
Journal:  Transplant Proc       Date:  2013-06       Impact factor: 1.066

Review 6.  Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.

Authors:  Vesna Risso; Elodie Lafont; Matthieu Le Gallo
Journal:  Cell Death Dis       Date:  2022-03-17       Impact factor: 9.685

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.